Boehringer Ingelheim Corp. says the National Advertising Division’s recommendation to pull the “maximum strength” claim for its DulcoGas product runs counter to FDA’s OTC anti-flatulent monograph and to a common advertising practice for multi-product lines.
NAD, reviewing a challenge brought by the marketer of the competing brand Gas-X, Novartis Consumer Health Inc., said the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?